Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

208 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-18

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, multi-centre, objective performance criteria clinical trial to evaluate the safety and efficacy of FemFlow Drug-Eluting Peripheral Balloon Catheter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for lesions with femoropopliteal artery stenosis or occlusion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Peripheral Artery Stenosis or Occlusion

NCT03844724

Peripheral Arterial Disease Iliac Artery Stenosis Femoral Artery Stenosis +4 more

COMPLETED NA

A Study of The Femoral Popliteal Artery Treated With LEGFLOW OTW

NCT02965677

Peripheral Arterial Disease

UNKNOWN NA

DCB Compared Stenting in Popliteal Lesions

NCT03739580

Popliteal Stenosis Popliteal Artery Occlusion Diabetes

UNKNOWN NA

A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW

NCT02962232

Peripheral Artery Disease

UNKNOWN NA

Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia

NCT05498740

Peripheral Arterial Disease (PAD)

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, multi-centre, single-group target value clinical study. Taking the patency rate at 12 months after operation as the primary evaluation index and taking target vascular cavity loss rate at 6 months postoperatively, Rutherford Classification at 12 months postoperatively, the ankle/brachial index (ABI), revascularization rate of target lesions, revascularization rate of target vessels, operating success rate and success rate of surgery as the secondary evaluation indexes to evaluate the efficacy of FemFlow Drug-Eluting Peripheral Balloon Catheter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for lesions with femoropopliteal artery stenosis or occlusion. Taking the incidence of major adverse events (MAE), adverse events (AE) and instrument defects occurred through the entire trail as the evaluation indexes to evaluate the safety of FemFlow Drug-Eluting Peripheral Balloon Catheter manufactured by Lifetech Scientific (Shenzhen) Company for lesions with femoropopliteal artery stenosis or occlusion. According to statistical hypothesis and sample size calculation, the sample size of this clinical trial was 208 cases. All subjects were followed up 1 month, 6 months and 12 months after treatment with a FemFlow Drug-Eluting Peripheral Balloon Catheter, and data on efficacy and safety were collected. All relevant clinical data are managed and analyzed by the professional data management centre and the statistical centre. End-point events of clinical trials are determined by a specially established third party.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Femoral Artery Stenosis Femoral Artery Occlusion Popliteal Arterial Stenosis Popliteal Artery Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

interventional arm

Participants will be treated with FemFlow Drug-Eluting Peripheral Balloon Catheter.

Group Type EXPERIMENTAL

FemFlow Drug-Eluting Peripheral Balloon Catheter

Intervention Type DEVICE

Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FemFlow Drug-Eluting Peripheral Balloon Catheter

Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Patients aged greater than 18 years old and less than 85 years old, regardless of gender；

2\. Patients with peripheral femoral or popliteal artery stenosis (greater than or equal to 70%) or occlusive disease;

3\. Rutherford classification graded 2-5；

4\. The subject or its legal representative can understand the purpose of the study, show sufficient compliance with the test protocol, and sign the informed consent.

Exclusion Criteria

* 1\. Patient with arteritis;

2\. Any acute thrombosis of target vessels requires thrombolysis or thrombectomy, or accepted local or systemic thrombolysis within 48 hours；

3\. Any cerebrovascular accidents within 3 months；

4\. Any unstable coronary heart disease or myocardial infarction within 3 months；

5\. Any important organ failure；

6\. Any known hypersensitivity to heparin, aspirin, clopidogrel, paclitaxel, paclitaxel compounds and contrast agents;

7\. Cannot accept antiplatelet and/or anticoagulation therapy；

8\. Patients with hemorrhagic physical diseases；

9\. Alanine transaminase (ALT) or Aspartate transaminase (AST) were five times higher than the normal upper limit；

10\. Serum creatinine \> 2mg/dl (177umol/L)；

11\. Pregnant or lactating woman；

12\. In the absence of intervention, the three lumens of tibialis anterior, tibialis posterior and peroneal artery stenosis or occlusion degree were all \>50%；

13\. iliac artery stenosis \>50%, or lumen stenosis \>50% after treatment (Limited to non-drug-eluting balloon or stent treatment only)；

14\. The guide wire cannot pass through target lesions (Passing through target lesions refers to the head of the guidewire arrive beyond the lesion in the absence of interlayer or perforation)；

15\. Severe calcification at target lesions and should not be treated with balloon dilatation therapy;

16\. Pre-dilation or anticipated severe vascular dissections after dilation;

17\. Residual stricture of \>50% or severe current-limiting dissection after pre-dilation is not suitable for simple balloon dilatation catheter treatment;

18\. The total length of target lesions is \>200mm, or the reference diameter of the target vessel was \>7mm or \<3mm;

19\. Life expectancy is less than one year;

20\. Participated in clinical trials of other drugs or instruments at the same time;

21\. Other conditions not suitable for inclusion judged by researchers.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guowei Fu

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.